Apparently Healthy People Aged 55 and OverNCT03151824
Gender-specific Associations Between Quality of Life and Leukocyte Telomere Length
An observational study of Apparently Healthy People Aged 55 and Over, run by Jung-Ha Kim.
Trial summary
Quality of life (QoL) is an important factor for successful aging. Telomere length is an indicator of cellular aging and cumulative biological stress and is thus related to health status and survival. However, the relationship between QoL and telomere length has not yet been examined. Read more about this study
- Who is it for?
- Ages 55 years and olderHealthy volunteers can take part
- Conditions the study is for
- Apparently Healthy People Aged 55 and Over
- What is being tested?
- quality of life
- How many people
- 164 participants
- Where
- No sites listed yet
- Study dates
- 25 Oct 2013to 24 Oct 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: A total of 164 apparently healthy subjects (82 couples) aged 55 and over were included in this study.
Who may be able to join
- married couple
- apparently healthy subjects above 55 years
Who cannot join
- Subjects who had experienced hormone therapy
- Subjects who had been diagnosed with dementia, Parkinson's disease, stroke, ischemic heart disease, congestive heart failure, arrhythmia, depression, cancer, thyroid disorders, or chronic renal disease
About this study
Official title: Gender-specific Associations Between Quality of Life and Leukocyte Telomere Length: A Cross-sectional Study
Quality of life (QoL) is an important factor for successful aging. Telomere length is an indicator of cellular aging and cumulative biological stress and is thus related to health status and survival. However, the relationship between QoL and telomere length has not yet been examined. In this study we investigated the relationship between leukocyte telomere length (LTL) and QoL.
However, the relationship between overall QoL and LTL has not previously been investigated. Therefore, this study was conducted to examine the relationship between LTL and QoL. QoL was measured by the Korean version of the 36-item short-form health survey (SF-36), which is a multidimensional scale consisting of subjective evaluation.
- Being tested
- quality of life
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
quality of lifeOther
Quality of life which was measured by the Korean version of the 36-item short-form health survey (SF-36)
What is being measured
The primary outcome is the main question the study is designed to answer.
leukocyte telomere length
Leukocyte telomere length was measured as telomere repeat copy number relative to single gene copy number by quantitative real-time PCR
Measured: 8months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 May 2017
- Study start25 Oct 2013
- Primary completion24 Oct 2014
- Study completion24 Oct 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Apparently Healthy People Aged 55 and OverStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 164 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jung-Ha Kim
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Jung-Ha Kim, Chung-Ang University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03151824
- Sponsor's protocol ID
- C 2013152(1112)
- Status last verified
- May 2017
- First submitted
- 11 May 2017
- Last updated
- 12 May 2017
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Gender-specific Associations Between Quality of Life and Leukocyte Telomere Length: A Cross-sectional Study
- ClinicalTrials.gov ID
- NCT03151824
- Acronym / sponsor ID
- C 2013152(1112)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 164 participants (actual)
- Lead sponsor
- Jung-Ha KimUniversity, hospital or other
- Study start
- 25 Oct 2013 (actual)
- Primary completion
- 24 Oct 2014 (actual)
- Study completion
- 24 Oct 2014 (actual)
- First posted
- 12 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Quality of life (QoL) is an important factor for successful aging. Telomere length is an indicator of cellular aging and cumulative biological stress and is thus related to health status and survival. However, the relationship between QoL and telomere length has not yet been examined. In this study we investigated the relationship between leukocyte telomere length (LTL) and QoL.
However, the relationship between overall QoL and LTL has not previously been investigated. Therefore, this study was conducted to examine the relationship between LTL and QoL. QoL was measured by the Korean version of the 36-item short-form health survey (SF-36), which is a multidimensional scale consisting of subjective evaluation.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- A total of 164 apparently healthy subjects (82 couples) aged 55 and over were included in this study.
Key inclusion criteria (2 listed)
- married couple
- apparently healthy subjects above 55 years
Key exclusion criteria (2 listed)
- Subjects who had experienced hormone therapy
- Subjects who had been diagnosed with dementia, Parkinson's disease, stroke, ischemic heart disease, congestive heart failure, arrhythmia, depression, cancer, thyroid disorders, or chronic renal disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| quality of lifeQuality of life which was measured by the Korean version of the 36-item short-form health survey (SF-36) | Other | – |
Primary outcome
leukocyte telomere length
Time frame: 8months
Leukocyte telomere length was measured as telomere repeat copy number relative to single gene copy number by quantitative real-time PCR
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2017.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Apparently Healthy People Aged 55 and Over, run by Jung-Ha Kim.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 May 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
leukocyte telomere length (time frame: 8months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2017.